Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2008

View Archived Issues

AT1-AAs implicated in pre-eclampsia in mouse studies

Novel treatment options for anemia described in recent GSK patent

NeoPharm reveals new agents for atopic dermatitis in recent patent

Subtype-selective GABA-A receptor modulator reduces neuropathic hypersensitivity in vivo

RGH-478 reduces pain in arthritis models

Biogen commences phase III Adentri trial in acute decompensated heart failure

Glycine transporter inhibitors identified at Merck for the treatment of schizophrenia

Pilot study finds no effect of atorvastatin on CSF HIV-1 infection

FRANCIS trial commences in patients within acute coronary syndrome

Indevus completes patient enrollment in phase III PRO-2000 trial

MMRC and Celgene collaborate on phase I/II pomalidomide trial

Alpharma rejects takeover proposal from King Pharmaceuticals

BioAlliance is granted main patent in Europe for Lauriad

Recent Mitsubishi Tanabe patent discloses new anxiolytic compounds

rhNRG-1 improves donor heart preservation in animal studies

Biovail gains Canadian approval for Ralivia for moderately severe pain

Generex signs oral insulin distribution deal with Dong-Sung for Korea

Invitrogen plans meeting for proposed merger with Applied Biosystems

Oxygen Biotherapeutics to meet with FDA for proposed phase IIb Oxycyte trial

QLT enters into exclusive license agreement with Reckitt for Atrigel technology

NeuroDiscovery reports results from phase IIa clinical trials of NSL-101 in dental surgery

Resverlogix initiates phase Ib/IIa program for RVX-208

Recent Janssen patent imparts new therapeutic agents for gastrointestinal disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...